Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Grazisa Rossetti.
PLOS Biology | 2011
Barbara Celona; Assaf Weiner; Francesca Di Felice; Francesco M. Mancuso; Elisa Cesarini; Riccardo L. Rossi; Lorna Gregory; Dilair Baban; Grazisa Rossetti; Paolo Grianti; Massimiliano Pagani; Tiziana Bonaldi; Jiannis Ragoussis; Nir Friedman; Giorgio Camilloni; Marco Bianchi; Alessandra Agresti
The basic unit of genome packaging is the nucleosome, and nucleosomes have long been proposed to restrict DNA accessibility both to damage and to transcription. Nucleosome number in cells was considered fixed, but recently aging yeast and mammalian cells were shown to contain fewer nucleosomes. We show here that mammalian cells lacking High Mobility Group Box 1 protein (HMGB1) contain a reduced amount of core, linker, and variant histones, and a correspondingly reduced number of nucleosomes, possibly because HMGB1 facilitates nucleosome assembly. Yeast nhp6 mutants lacking Nhp6a and -b proteins, which are related to HMGB1, also have a reduced amount of histones and fewer nucleosomes. Nucleosome limitation in both mammalian and yeast cells increases the sensitivity of DNA to damage, increases transcription globally, and affects the relative expression of about 10% of genes. In yeast nhp6 cells the loss of more than one nucleosome in four does not affect the location of nucleosomes and their spacing, but nucleosomal occupancy. The decrease in nucleosomal occupancy is non-uniform and can be modelled assuming that different nucleosomal sites compete for available histones. Sites with a high propensity to occupation are almost always packaged into nucleosomes both in wild type and nucleosome-depleted cells; nucleosomes on sites with low propensity to occupation are disproportionately lost in nucleosome-depleted cells. We suggest that variation in nucleosome number, by affecting nucleosomal occupancy both genomewide and gene-specifically, constitutes a novel layer of epigenetic regulation.
Nature Immunology | 2015
Valeria Ranzani; Grazisa Rossetti; Ilaria Panzeri; Alberto Arrigoni; Raoul J. P. Bonnal; Serena Curti; Paola Gruarin; Elena Provasi; Elisa Sugliano; Maurizio Marconi; Raffaele De Francesco; Jens Geginat; Beatrice Bodega; Sergio Abrignani; Massimiliano Pagani
Long noncoding RNAs are emerging as important regulators of cellular functions, but little is known of their role in the human immune system. Here we investigated long intergenic noncoding RNAs (lincRNAs) in 13 subsets of T lymphocytes and B lymphocytes by next-generation sequencing–based RNA sequencing (RNA-seq analysis) and de novo transcriptome reconstruction. We identified over 500 previously unknown lincRNAs and described lincRNA signatures. Expression of linc-MAF-4, a chromatin-associated lincRNA specific to the TH1 subset of helper T cells, was inversely correlated with expression of MAF, a TH2-associated transcription factor. Downregulation of linc-MAF-4 skewed T cell differentiation toward the TH2 phenotype. We identified a long-distance interaction between the genomic regions of the gene encoding linc-MAF-4 and MAF, where linc-MAF-4 associated with the chromatin modifiers LSD1 and EZH2; this suggested that linc-MAF-4 regulated MAF transcription through the recruitment of chromatin modifiers. Our results demonstrate a key role for lincRNA in T lymphocyte differentiation.
Immunity | 2016
Marco De Simone; Alberto Arrigoni; Grazisa Rossetti; Paola Gruarin; Valeria Ranzani; Claudia Politano; Raoul J. P. Bonnal; Elena Provasi; Maria Lucia Sarnicola; Ilaria Panzeri; Monica Moro; Mariacristina Crosti; Saveria Mazzara; Valentina Vaira; Silvano Bosari; Alessandro Palleschi; Luigi Santambrogio; Giorgio Bovo; Nicola Zucchini; Mauro Totis; Luca Gianotti; Giancarlo Cesana; R Perego; Nirvana Maroni; Andrea Pisani Ceretti; Enrico Opocher; Raffaele De Francesco; Jens Geginat; Hendrik G. Stunnenberg; Sergio Abrignani
Summary Tumor-infiltrating regulatory T lymphocytes (Treg) can suppress effector T cells specific for tumor antigens. Deeper molecular definitions of tumor-infiltrating-lymphocytes could thus offer therapeutic opportunities. Transcriptomes of T helper 1 (Th1), Th17, and Treg cells infiltrating colorectal or non-small-cell lung cancers were compared to transcriptomes of the same subsets from normal tissues and validated at the single-cell level. We found that tumor-infiltrating Treg cells were highly suppressive, upregulated several immune-checkpoints, and expressed on the cell surfaces specific signature molecules such as interleukin-1 receptor 2 (IL1R2), programmed death (PD)-1 Ligand1, PD-1 Ligand2, and CCR8 chemokine, which were not previously described on Treg cells. Remarkably, high expression in whole-tumor samples of Treg cell signature genes, such as LAYN, MAGEH1, or CCR8, correlated with poor prognosis. Our findings provide insights into the molecular identity and functions of human tumor-infiltrating Treg cells and define potential targets for tumor immunotherapy.
PLOS ONE | 2013
Paola de Candia; Anna Torri; Tatiana Gorletta; Maya Fedeli; Elisabetta Bulgheroni; Cristina Cheroni; Francesco Marabita; Mariacristina Crosti; Monica Moro; Elena Pariani; Luisa Romanò; Susanna Esposito; Fabio Mosca; Grazisa Rossetti; Riccardo L. Rossi; Jens Geginat; Giulia Casorati; Paolo Dellabona; Massimiliano Pagani; Sergio Abrignani
Activated lymphocytes release nano-sized vesicles (exosomes) containing microRNAs that can be monitored in the bloodstream. We asked whether elicitation of immune responses is followed by release of lymphocyte-specific microRNAs. We found that, upon activation in vitro, human and mouse lymphocytes down-modulate intracellular miR-150 and accumulate it in exosomes. In vivo, miR-150 levels increased significantly in serum of humans immunized with flu vaccines and in mice immunized with ovalbumin, and this increase correlated with elevation of antibody titers. Immunization of immune-deficient mice, lacking MHCII, resulted neither in antibody production nor in elevation of circulating miR-150. This study provides proof of concept that serum microRNAs can be detected, with minimally invasive procedure, as biomarkers of vaccination and more in general of adaptive immune responses. Furthermore, the prompt reduction of intracellular level of miR-150, a key regulator of mRNAs critical for lymphocyte differentiation and functions, linked to its release in the external milieu suggests that the selective extracellular disposal of microRNAs can be a rapid way to regulate gene expression during lymphocyte activation.
Cerebral Cortex | 2016
Francesco Bedogni; Clementina Cobolli Gigli; Davide Pozzi; Riccardo L. Rossi; Linda Scaramuzza; Grazisa Rossetti; Massimiliano Pagani; Charlotte Kilstrup-Nielsen; Michela Matteoli; Nicoletta Landsberger
MeCP2 is associated with several neurological disorders; of which, Rett syndrome undoubtedly represents the most frequent. Its molecular roles, however, are still unclear, and data from animal models often describe adult, symptomatic stages, while MeCP2 functions during embryonic development remain elusive. We describe the pattern and timing of Mecp2 expression in the embryonic neocortex highlighting its low but consistent expression in virtually all cells and show the unexpected occurrence of transcriptional defects in the Mecp2 null samples at a stage largely preceding the onset of overt symptoms. Through the deregulated expression of ionic channels and glutamatergic receptors, the lack of Mecp2 during early neuronal maturation leads to the reduction in the neuronal responsiveness to stimuli. We suggest that such features concur to morphological alterations that begin affecting Mecp2 null neurons around the perinatal age and become evident later in adulthood. We indicate MeCP2 as a key modulator of the transcriptional mechanisms regulating cerebral cortex development. Neurological phenotypes of MECP2 patients could thus be the cumulative result of different adverse events that are already present at stages when no obvious signs of the pathology are evident and are worsened by later impairments affecting the central nervous system during maturation and maintenance of its functionality.
PLOS Genetics | 2017
Piera Calamita; Annarita Miluzio; Arianna Russo; Elisa Pesce; Sara Ricciardi; Farhat L. Khanim; Cristina Cheroni; Roberta Alfieri; Marilena Mancino; Chiara Gorrini; Grazisa Rossetti; Ivana Peluso; Massimiliano Pagani; Diego L. Medina; Johanna M. Rommens; Stefano Biffo
Ribosomopathies are a family of inherited disorders caused by mutations in genes necessary for ribosomal function. Shwachman-Diamond Bodian Syndrome (SDS) is an autosomal recessive disease caused, in most patients, by mutations of the SBDS gene. SBDS is a protein required for the maturation of 60S ribosomes. SDS patients present exocrine pancreatic insufficiency, neutropenia, chronic infections, and skeletal abnormalities. Later in life, patients are prone to myelodisplastic syndrome and acute myeloid leukemia (AML). It is unknown why patients develop AML and which cellular alterations are directly due to the loss of the SBDS protein. Here we derived mouse embryonic fibroblast lines from an SbdsR126T/R126T mouse model. After their immortalization, we reconstituted them by adding wild type Sbds. We then performed a comprehensive analysis of cellular functions including colony formation, translational and transcriptional RNA-seq, stress and drug sensitivity. We show that: 1. Mutant Sbds causes a reduction in cellular clonogenic capability and oncogene-induced transformation. 2. Mutant Sbds causes a marked increase in immature 60S subunits, limited impact on mRNA specific initiation of translation, but reduced global protein synthesis capability. 3. Chronic loss of SBDS activity leads to a rewiring of gene expression with reduced ribosomal capability, but increased lysosomal and catabolic activity. 4. Consistently with the gene signature, we found that SBDS loss causes a reduction in ATP and lactate levels, and increased susceptibility to DNA damage. Combining our data, we conclude that a cell-specific fragile phenotype occurs when SBDS protein drops below a threshold level, and propose a new interpretation of the disease.
Proceedings of the National Academy of Sciences of the United States of America | 2016
Maya Fedeli; Michela Riba; Jose Manuel Garcia Manteiga; Lei Tian; Valentina Viganò; Grazisa Rossetti; Massimiliano Pagani; Changchun Xiao; Adrian Liston; Elia Stupka; Davide Cittaro; Sergio Abrignani; Paolo Provero; Paolo Dellabona; Giulia Casorati
Significance CD1d-restricted invariant natural killer T (iNKT) cells are innate-like T lymphocytes that play fundamental roles in cancer, autoimmunity, and infections. iNKT cells acquire effector functions already in the thymus, because of a distinct developmentally regulated genetic program that is critically controlled by miRNAs. Our study unveils the unexpected requirement for miRNA-dependent fine-tuning of TGF-β signaling in the control of iNKT cell development and functional differentiation. The targeting of a lineage-specific cytokine signaling by miRNA represents a previously unknown level of developmental regulation in the thymus. Furthermore, our study provides a comprehensive atlas of miRNA-regulated molecular pathways involved in iNKT cell ontogenesis, and highlights molecular pathways targeted by defined miRNAs that are predicted to be involved in the development and maturation of CD1d-restricted iNKT cells. Invariant natural killer T cells (iNKT) cells are T lymphocytes displaying innate effector functions, acquired through a distinct thymic developmental program regulated by microRNAs (miRNAs). Deleting miRNAs by Dicer ablation (Dicer KO) in thymocytes selectively impairs iNKT cell survival and functional differentiation. To unravel this miRNA-dependent program, we systemically identified transcripts that were differentially expressed between WT and Dicer KO iNKT cells at different differentiation stages and predicted to be targeted by the iNKT cell-specific miRNAs. TGF-β receptor II (TGF-βRII), critically implicated in iNKT cell differentiation, was found up-regulated in iNKT Dicer KO cells together with enhanced TGF-β signaling. miRNA members of the miR-17∼92 family clusters were predicted to target Tgfbr2 mRNA upon iNKT cell development. iNKT cells lacking all three miR-17∼92 family clusters (miR-17∼92, miR-106a∼363, miR-106b∼25) phenocopied both increased TGF-βRII expression and signaling, and defective effector differentiation, displayed by iNKT Dicer KO cells. Consistently, genetic ablation of TGF-β signaling in the absence of miRNAs rescued iNKT cell differentiation. These results elucidate the global impact of miRNAs on the iNKT cell developmental program and uncover the targeting of a lineage-specific cytokine signaling by miRNAs as a mechanism regulating innate-like T-cell development and effector differentiation.
Journal of Internal Medicine | 2014
I. De Toma; Grazisa Rossetti; Samuel Zambrano; Marco Bianchi; Alessandra Agresti
High mobility group box 1 (HMGB1) is a small nuclear protein with two functions. In the nucleus, it helps to wrap DNA around nucleosomes. When secreted, it recruits inflammatory cells and induces cytokine production. Before HMGB1 is secreted from inflammatory cells, it relocates to the cytoplasm, which partially or totally depletes cell nuclei of HMGB1. We previously showed that cells lacking HMGB1 contain 20% fewer nucleosomes and 30% more RNA transcripts levels genome‐wide.
Proceedings of the National Academy of Sciences of the United States of America | 2017
A. Ripamonti; Elena Provasi; M. Lorenzo; M. De Simone; Valeria Ranzani; S. Vangelisti; S. Curti; Raoul J. P. Bonnal; Lorenzo Pignataro; S. Torretta; Jens Geginat; Grazisa Rossetti; Massimiliano Pagani; Sergio Abrignani
Significance Antibody production by B lymphocytes generally requires help by T follicular helper (TFH) cells, a specific subset of CD4+ T lymphocytes. The function of TFH cells depends on BCL6, a transcriptional repressor whose target genes that account for the helper activity are unknown. By the combined analysis of microRNA (miRNA) and gene expression profiling in human TFH cells, we found that miR-31, a miRNA that inhibits gene transcripts relevant for TFH cells biology, is down-regulated in TFH. BCL6 contributes to “helperness” by shutting down miR-31 gene expression, thus stabilizing the follicular helper T cell program. Thus miR-31 is a therapeutic target to modulate human T cell-dependent antibody responses in immunomediated disorders. Follicular helper T cells (TFHs) are a key component of adaptive immune responses as they help antibody production by B cells. Differentiation and function of TFH cells are controlled by the master gene BCL6, but it is largely unclear how this transcription repressor specifies the TFH program. Here we asked whether BCL6 controlled helper function through down-regulation of specific microRNAs (miRNAs). We first assessed miRNA expression in TFH cells and defined a TFH-specific miRNA signature. We report that hsa–miR-31–5p (miR-31) is down-regulated in TFH; we showed that BCL6 suppresses miR-31 expression by binding to its promoter; and we demonstrated that miR-31 inhibits the expression of molecules that control T-helper function, such as CD40L and SAP. These findings identify a BCL6-initiated inhibitory circuit that stabilizes the follicular helper T cell program at least in part through the control of miRNA transcription. Although BCL6 controls TFH activity in human and mouse, the role of miR-31 is restricted to human TFH cell differentiation, reflecting a species specificity of the miR-31 action. Our findings highlight miR-31 as a possible target to modulate human T cell dependent antibody responses in the settings of infection, vaccination, or immune dysregulation.
Methods of Molecular Biology | 2016
Alberto Arrigoni; Valeria Ranzani; Grazisa Rossetti; Ilaria Panzeri; Sergio Abrignani; Raoul J. P. Bonnal; Massimiliano Pagani
RNA-Seq is an approach to transcriptome profiling that uses deep-sequencing technologies to detect and accurately quantify RNA molecules originating from a genome at a given moment in time. In recent years, the advent of RNA-Seq has facilitated genome-wide expression profiling, including the identification of novel and rare transcripts like noncoding RNAs and novel alternative splicing isoforms.Here, we describe the analytical steps required for the identification and characterization of noncoding RNAs starting from RNA-Seq raw samples, with a particular emphasis on long noncoding RNAs (lncRNAs).